VB100 Spring Strategic Launch Event Concludes Successfully with Five Major Announcements

On March 26, 2019, the VB100 New Year Strategy Launch Day, hosted by VCBeat, successfully concluded at LSPACE in the 813 Creative Industrial Park in Beijing.

VB100 Launch Day is China’s first launch day dedicated to the healthcare industry and one of VCBeat’s flagship events. VCBeat brings together the most prominent listed companies, unicorns, and leading innovative enterprises in niche sectors within the healthcare field to announce major strategic updates, including new product launches, financing rounds, partnerships, reports, and business plans. The event also invites dozens of professional media outlets from the healthcare, technology, and venture capital/finance industries to attend, creating a coordinated online presence across all platforms. It serves startups, listed companies, investment institutions, healthcare service providers, industrial parks, and government agencies that have needs for information dissemination within the healthcare industry.

VB100 Spring Festival Strategy Launch Event Site

As VCBeat’s first major announcement of the new year, this launch event brought together five enterprises/institutions/organizations: BMJ, the China Medical Imaging AI Industry-Academia-Research-Application Innovation Alliance, Yitu Healthcare, Infervision, and Yu Jian Wei Lai. In addition to traditional mainstream media, VCBeat partnered with 50 leading media outlets from the healthcare, finance, and technology sectors to jointly witness the release of five major announcements.

1. BMJ Launches BMJ Best Practice: China’s First Fully Chinese-Language, Multimodal Evidence-Based Clinical Decision Support System Debuts

At the first press conference of this event, Kong Yuyan, Managing Director of BMJ China, outlined the value and philosophy of BMJ Best Practice (hereinafter referred to as BP). Ren Ran, Product Manager at BMJ China, provided a detailed introduction to the content and format of BP. Du Xin, Clinical Advisor at BMJ China, and Associate Professor Wu Dong from the Department of Gastroenterology at Peking Union Medical College Hospital, who also serves as Director of the National Health Commission’s Youth Innovation Center, conducted a demonstration of BP’s application.

BMJ Launches BMJ Best Practice for Clinical Practice

BMJ Best Practice Clinical Practice, abbreviated as BP, is a world-class evidence-based clinical decision support system. This product provides physicians with authoritative and practical evidence-based diagnostic and treatment knowledge, helping them formulate and optimize their clinical decisions anytime and anywhere.

The Chinese version of BP is credible, efficient, extremely low-cost to implement, and widely accessible. It delivers immense value in enhancing both the individual clinical capabilities of Chinese physicians and the overall quality and efficiency of healthcare institutions.

“Everyone should recognize that doctors in China face a variety of challenges every day. A typical internal medicine physician at a tertiary Grade A hospital needs to see approximately 40–50 patients, or even more, during a half-day outpatient session. They must rapidly formulate diagnosis and treatment plans for these patients. Additionally, they are required to keep pace with scientific advancements in their specialty, stay abreast of the latest evidence, read new literature amounting to over ten kilograms annually, and attend dozens of academic events. It is an unimaginable task to timely acquire diagnostic and therapeutic knowledge outside their own specialty and apply it in clinical practice. BP, however, effectively helps physicians address this challenge through its authoritative, multidisciplinary knowledge base and its instantly accessible format,” stated Kong Yuyan, Managing Director of BMJ China, at the event.

Founded in 1840 and affiliated with the British Medical Association, BMJ is a leading international publisher of medical knowledge. Its flagship journal, The BMJ, is one of the four most prestigious general medical journals worldwide. BMJ Best Practice, its clinical practice resource, is a world-class evidence-based clinical decision support system.

Following the 2018 collaboration with Jiahemed, a leader in medical artificial intelligence, which pioneered a novel model combining an “evidence-based medicine knowledge base” with “machine learning on high-quality medical records,” BMJ has now launched the full suite of multimodal BMJ Best Practice products. This milestone establishes BP as the first evidence-based medicine tool capable of comprehensively and instantly supporting clinical decision-making for physicians in China through web platforms, mobile applications, and intelligent integration with electronic medical records (EMR), holding significant implications for improving healthcare quality and efficiency.

2. Yu Jian Future Launches Service Platform for Patients with Cardiovascular and Cerebrovascular Diseases, Benefiting Over 24 Million Patients

At the second press conference of the event, Yujian Weilai launched the Walnut Doctor platform and its Light Rehabilitation model, providing professional and authoritative prevention, diagnosis, treatment, and rehabilitation services to over 24 million cardiovascular and cerebrovascular disease patients in China, thereby enhancing industry-wide attention and influence.

Yujian Future Launches Walnut Doctor Platform and Light Rehabilitation Model

1. The Walnut Doctor platform is currently a public account. It is based on WeChat and has also established a presence on Baijiahao, Sohu, Sina, and Douyin. The content currently provided by the official account includes:

1. Very basic science popularization education, with all such educational content provided by top-tier tertiary hospitals like Xuanwu Hospital;

2. Expert consultations and lectures, with physicians from Xuanwu Hospital occasionally conducting online video lectures;

3. Provide appointment scheduling services.

4. Established a patient community.

II. The light rehabilitation model relies on a highly portable device with excellent clinical utility. Developed by Professor Ji Xunming of Xuanwu Hospital, Capital Medical University, this portable rehabilitation device enables home-based rehabilitation for cerebrovascular and cardiovascular diseases. Its form factor is similar to that of a blood pressure monitor. Compared with surgical treatment, it is less invasive and can facilitate long-term improvement in patients’ underlying physiological mechanisms.

3. “White Paper on AI in Chinese Medical Imaging”: Charting a New Development Blueprint for Medical Imaging AI Enterprises

At the third press conference, Liu Shiyuan, Chairman of the China Medical Imaging AI Industry-Academia-Research-Application Innovation Alliance, took the stage to deliver a speech. He stated that the alliance’s work aims to promote industry development, with the *White Paper on Medical Imaging AI in China* being one of its key initiatives. The white paper encompasses six aspects of work and content, representing the collective efforts and insights of stakeholders across all sectors—industry, academia, research, and application—and stands as the most authoritative voice in China’s current AI landscape.

“White Paper on AI in Chinese Medical Imaging” Officially Released

Qian Dahong, Chairman of the China Medical Imaging AI Industry-Academia-Research-Application Innovation Alliance, introduced key highlights of the White Paper on Medical Imaging AI in China to the attendees. Finally, members of the White Paper Editorial Committee and representatives from leading artificial intelligence enterprises took the stage to participate in the launch ceremony, jointly witnessing this exciting moment. The release of this White Paper will help industry stakeholders analyze development trends and identify appropriate strategic pathways.

It is reported that the application of AI in medical imaging has witnessed vigorous growth in recent years, with continuous academic and commercial achievements. However, this rapid expansion has also given rise to significant hype and market irregularities. Against this backdrop, the China Medical Imaging AI Industry-Academia-Research-Application Innovation Alliance convened radiology experts from domestic Grade 3A hospitals, research specialists, and leading AI medical companies to jointly draft the professional “White Paper on Medical Imaging AI in China.”

The “White Paper on AI in Chinese Medical Imaging” is the most authoritative report and serves as a strategic roadmap for the development of enterprises in the medical imaging AI sector. The report provides an in-depth analysis across six key dimensions: applications of artificial intelligence in healthcare, recent advances in medical imaging AI algorithms, demand assessment for medical imaging AI, current status and prospects of clinical adoption, policy landscape, and challenges and recommendations.

The report also analyzes the developmental value of AI in medical imaging across 15 major clinical applications, providing stakeholders with a profound understanding of industry development models and opportunities. It introduces over 40 representative AI-in-medical-imaging companies, offering enterprises a comprehensive strategic framework and direction for growth. Furthermore, it provides an in-depth analysis of the challenges and opportunities posed by current policies to AI in medical imaging, putting forward constructive recommendations to help industry stakeholders decipher policy trends and identify appropriate development strategies.

4. “AI + Cloud” Empowers Chinese Pediatrics: Yitu Healthcare Officially Launches Intelligent Cloud Platform for Child Health

Yitu Healthcare, the leading recipient of AI healthcare financing with $300 million in funding, has emerged as a dark horse over the past year, becoming China’s first unicorn enterprise in the fields of medical big data and artificial intelligence. Previously, Yitu Healthcare launched the “AI Cancer Prevention Map” initiative, covering 19 provinces, municipalities, and autonomous regions and involving hundreds of medical institutions. This initiative leverages AI applications to empower early cancer screening, expanding the use cases of medical AI from healthcare institutions to the broader field of health management, thereby ushering public health management in China into the “AI+” era.

Dr. Fang Cong, Vice President of Yitu Healthcare

The newly released Intelligent Cloud Platform for Children's Health represents a breakthrough integration of world-class AI technologies in text, imaging, and speech. It achieves comprehensive coverage across all scenarios—from child health assessment to pediatric diagnosis and treatment services—spanning pre-consultation, intra-consultation, and post-consultation phases. This marks a significant milestone in the AI healthcare industry, shifting from successful applications in single tasks or specific disease sites to a major breakthrough centered on pediatric patients.

Dr. Fang Cong, Vice President of Yitu Healthcare, stated on-site, “After several years of development, Yitu Healthcare has established a comprehensive AI product matrix for pediatrics that spans the entire continuum of care, both within and outside hospital settings. Currently, this cloud platform offers dozens of AI-powered services, including intelligent triage, smart pre-consultation inquiries, automated pre-diagnostic testing, and voice-enabled electronic medical records. These solutions cover various scenarios across pre-diagnosis, intra-diagnosis, post-diagnosis, hospital management, and clinical research. This initiative will further accelerate the intelligent transformation of China’s pediatric sector, empowering every link in the healthcare journey—both inside and outside hospitals—with advanced AI products, thereby supporting both healthcare providers and patients and alleviating the challenges associated with pediatric care.”

5. Infervision Launches Advanced AI Scholar Research Platform, Enabling Medical Researchers Without Programming Skills to Conduct Deep Learning Research

As the first deep medical AI company in China to achieve clinical application, Infervision has leveraged deep learning technology since its inception to analyze medical imaging data such as DR, CT, and MRI. It provides physicians with precise and efficient auxiliary tools, collaborates with over 250 hospitals worldwide, has assisted in the diagnosis of more than 2.5 million patients, and completed over 200,000 imaging screening cases in real-world clinical practice. Infervision’s solutions have been implemented at Shanghai Changzheng Hospital, where they have received unanimous recognition from radiologists for significantly improving diagnostic efficiency.

Shen Yun, Dean of the Global Clinical Research Collaboration Academy and Chief Clinical Research Collaboration Scientist at Infervision

Leveraging its world-class technology and expertise, Infervision has launched the InferScholarTM Center AI Scholar Research Platform. Centered on the core philosophy of empowering medical research with deep learning, this platform enables medical researchers without computer programming skills to conduct deep learning-based scientific studies. It represents truly physician-led AI, serving as an exclusive research assistant for doctors and a powerful tool that allows more healthcare professionals to harness AI in the fight against disease.

This platform has four major features:

1. Visualized operation with no usage barriers, enabling participation by all physicians;

II. It is not merely an imaging system but also an AI platform capable of supporting a wide range of projects, including those initiated by clinicians across various specialties;

3. Integrated software and hardware solution, ensuring that data remains within the hospital;

IV. Beyond Imaging: Empowering Physicians to Be Not Only Users of AI, but Also Its Creators and Leaders.

The innovative healthcare industry is undergoing a paradigm shift, with new business models and technological applications continuously emerging. With the daily influx of information from new product launches, project initiations, successful funding rounds, and strategic realignments, truly transformative innovations that drive industry progress are sometimes drowned out by the noise.

VCBeat—A healthcare media outlet born in 2014, the inaugural year of China’s internet healthcare era. As an observer and recorder of the innovative healthcare industry, VCBeat has been continuously strengthening its core competency in “brand communication.” We have found that powerful brand communication capability consists of four key elements: communication heat sources, communication formats, channel influence, and potential energy factors, all of which adhere to the following “Brand Communication Power” law:

Brand Communication Power F = Communication Heat Source E × Communication Form α × Channel Influence β × Potential Energy Factor γ

Through this core formula, we believe that launching a highly ceremonial press conference to create a focal point and tipping point, followed by a round of promotional campaigns, is the most powerful way for enterprises and institutions to make their voices heard. Meanwhile, standalone information releases are fleeting in today’s sea of data, failing to generate significant impact within the industry; however, aggregating major announcements can yield greater momentum for dissemination.

In December 2018, VCBeat hosted China’s first healthcare industry launch event—the VB100 Launch Day. In collaboration with eight enterprises and institutions, including Alibaba Cloud, Deshang Yunxing, VoxelCloud, NVIDIA, Xiao Dou Miao & Mommy Knows, Yixu Medical, Health Benefit, and DHIC, we unveiled new developments across five key areas: new products, financing, reports, strategies, and partnerships. By concentrating the release of extensive information, we aimed to accelerate information equilibrium within the industry, thereby fostering technological innovation, breakthroughs, and industrial collaboration.

The five major announcements released at VB100’s New Year Strategy Launch Event will bring more positive impacts to the industry.

VB100 Spring Festival Strategy Launch Event

VCBeat will bring together the most closely watched listed companies, unicorns, and leading innovative enterprises in niche segments of the medical device industry. It will centrally release major announcements—including new products/projects, financing updates, partnership deals, data reports, and strategic plans—creating a clustering effect that generates substantial influence within the industry, thereby jointly staging the most notable launch event in the medical device sector in 2019. Meanwhile, VB100 Launch Day will invite dozens of traditional media outlets as well as media specializing in healthcare, technology, and finance to ensure in-depth dissemination and precisely reach target audiences.